Drugs · acquisition-cost intelligence
DOXYCYCLINE HYCLATE
· ingredient doxycyclineAntiinfectives and antiseptics for local oral treatment· DOXYCYCLINE HYCLATE 150 mg/1; DOXYCYCLINE HYCLATE 200 mg/1; DOXYCYCLINE HYCLATE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$3.33
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-01-222026-05-20
Same-ingredient options by acquisition cost
Other doxycycline products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Doxycycline Hyclate | $0.09492 | −$3.24 |
| Doxycyclate Hyclate | $0.11447 | −$3.22 |
| Doxycycline | $0.12382 | −$3.21 |
| doxycycline | $0.12382 | −$3.21 |
| doxycycline | $0.19532 | −$3.14 |
| DOXYCYCLINE | $0.22581 | −$3.11 |
| doxycycline | $0.23461 | −$3.10 |
| doxycycline | $0.23461 | −$3.10 |
Medicare Part D coverage · CY2026
On 13 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.